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Ab s t r Ac t
Introduction: Gingival overgrowth is one of several oral side effects of phenytoin, a potent antiepileptic drug. Several mechanisms have 
been elucidated to understand the pathogenesis of drug-induced gingival overgrowth. The frequency of gingival overgrowth associated with 
chronic phenytoin therapy remains controversial. Moreover, the possible subclinical effects of this drug on the gingival epithelium should be 
investigated histopathologically and immunohistochemically. Purpose of the Study: The purpose of the study was to investigate the Bcl-2 for 
apoptosis rate and Ki-67 for the epithelial proliferative activity in epileptic patients. Materials and Methods: Twenty-four samples of gingival 
tissue from epileptic patients treated with phenytoin and in eight samples of gingival tissue from healthy patients who did not use phenytoin 
(control) were evaluated for Bcl-2 and Ki-67 immunohistochemically. Results: The results revealed more proliferative activity of the overlying 
epithelium and an increased pattern of Bcl-2 and Ki-67 in phenytoin users compared to controls. Conclusion: These results concluded that 
the increased epithelial thickness observed in phenytoin-induced gingival overgrowth is associated with increased apoptotic rate and mitotic 
activity, especially in the oral epithelium.
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In t r o d u c t I o n
Gingival enlargement or overgrowth is the increase in size 
of the gingiva that caused by a variety of etiologic factors, 
including inflammation, adverse events, systemic diseases, 
genetic and neoplastic or false enlargement, as well as certain 
medications.[1-10] Drug-induced gingival overgrowth (DIGO) 
is an important side effect of prolonged intake certain drugs, 
such as anticonvulsants (phenytoin) immunosuppressants 
(cyclosporine) and calcium channel blockers (nifedipine).[11-16] 
Although these medications are usually associated with the 
development of gingival overgrowth, they continue to be 
the drugs of choice for the prevention of epileptic seizures, 
transplant rejection, and hypertension, respectively.[17-20] The 
mechanisms whereby drugs with different pharmacological 
actions induce different types of gingival overgrowth with 
relatively similar clinical and histopathological characteristics 
remain a matter of debate.[11,13,15-19]
Some studies proposed that DIGO could be induced by 
rupture of homeostasis between synthesis and degradation 
of collagen and other extracellular matrix components, as 
well as between cell proliferation and apoptosis involving the 
gingival epithelium and connective tissue.[21-26] Other series 
realized that the pathogenesis of DIGO has been related to the 
presence of a genetically determined subpopulation of drug-
sensitive fibroblasts, which may respond by increasing cell 
proliferation/survival or by altering the synthesis and remodeling 
of extracellular matrix.[27-32] In an attempt to better understand 
the pathogenesis of phenytoin as a DIGO, the present study 
evaluates the immunohistochemical expression of antiapoptotic 
protein Bcl-2 and the cell proliferation rates (Ki-67) in gingival 
overgrowth of epileptic patients using phenytoin and compared 
the findings with those observed for clinically healthy gingiva. 
In addition, the associations with histopathological features will 
establish.
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MAt e r I A l s A n d Me t h o d s
Study Cases
This retrospective study was conducted with the epileptic patients 
who had been referred for the management of their periodontal 
problems at the outpatient clinics of the Periodontology Department, 
Faculty of Dentistry, Al-Azhar University, Cairo, Egypt, during the period 
between 2015 G and 2018G. Twenty-four male patients were included 
in this study, ranging in ages from 15 to 35 years after obtaining 
approval from the university ethical committee and informed consent 
was obtained from the patient after thoroughly explaining the 
advantages and disadvantages of treatment procedures.
Gingival biopsies were collected from 24 epileptic subjects 
who had receiving phenytoin with moderate-to-severe gingival 
overgrowth during gingivectomy procedures. Normal healthy 
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gingival tissue samples without clinical signs of periodontal 
inflammation were also included as control samples. The control 
gingival tissue samples were taken from the marginal gingiva of 
eight patients of the same gender and age when they underwent 
routine dental treatment (e.g., tooth extraction for orthodontic 
reasons or crown lengthening procedures). The control subjects 
were recruited from the outpatient clinic at the Faculty of Dentistry, 
Al-Azhar University, Cairo, Egypt, during the same period. All 
patients signed a consent form after being advised of the nature 
of the study. Diagnosis was based on the detailed patients’ history 
and careful clinical examination, Figure 1a and b and Figure 2.
Tissue Processing
Gingival tissue samples of the 24 epileptic patients and the 8 
control subjects were fixed in 10% formalin and embedded in 
paraffin. Sections with 4 μm thickness were cut at the central 
region of each specimen to obtain maximum standardization of 
the cutting surface. Serial sections were taken from tissue blocks 
and processed for morphological and immunohistochemical 
examination. One section from each sample was stained with 
hematoxylin and eosin to evaluate the histopathological 
presentation of gingival enlargement in epileptic patients and 
normal gingival tissue in control samples.
Immunohistochemical Staining
Sections were deparaffinized in xylene and alcohol and rehydrated 
in graded alcohols. Slides were boiled in citrate buffer (pH 6.0) at 
95–100°C for 5 min and were cooled down for 20 min. Endogenous 
peroxide was blocked by 3% hydrogen peroxide in methanol for 
10 min. Sections were incubated with Bcl-2 monoclonal antibody 
(1:200, DAKO, Carpinteria, CA, USA) and a mouse anti-human Ki-67 
antibody (Zymed, CA, USA) for 1 h at 37°C, immunohistochemical 
staining. The chromogen substrate for the development of the 
peroxidase activity was 3,3-diaminobenzidine (DAKO, Cytomation, 
Carpinteria, CA, USA). All sections were counter stained with 
Meyer’s hematoxylin. The sections processed without the primary 
antibodies were used as negative control. Each step was followed 
by thorough washes with phosphate-buffered saline.
Evaluation of Immunostaining
Ordinary light microscope was first used to detect and localize the 
positive and negative Bcl-2 and Ki-67 immunostaining reaction 
within the gingival tissues in 10 representative fields for all Bcl-2 
and Ki-67 stained specimens. Epithelial cells of the gingival tissue 
with nuclear brown staining were considered positive, while 
negative immune reaction showed no brown staining.
Statistical Analysis
The obtained immunohistochemical results of all examined 
sections were given as mean values ± standard deviation for 
statistical evaluation. Chi-square test and Pearson correlation 
analysis were used to compare the overall expression of different 
proteins among the examined gingival tissue specimens. 
Differences were considered statistically significant when P < 0.05.
re s u lts
Histopathological and Immunohistochemical Findings
The histopathological features of the normal healthy tissue samples 
exhibited parakeratinized overlying epithelium with normal 
thickness and slightly elongated epithelial ridges extending into 
the underlying connective tissue layers. The connective tissue 
stroma showed normal amount of collagen fibers interspersed 
with variable numbers of fibroblasts and fibrocytes and some 
blood vessels, as well as few chronic inflammatory cell infiltrate, 
Figure 3.
Examination of H and E stained sections of moderate and severe 
cases of DIGO of epileptic patients revealed histopathological 
features that did not differ greatly between different cases. 
Figure 2: Clinical view of normal healthy gingival tissue
Figure 3: Histopathology of normal gingival tissues showing normal 
overlying epithelium and connective tissue (H and E ×100)
Figure 1: Clinical view of epileptic patients with moderate (a) and 
severe (b) gingival overgrowth, respectively
ba
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They shared a common histopathology of a significant papillary 
hyperplasia of the overlying epithelium and thick parakeratinized 
epithelial layer. Acanthosis and deep anastomosing epithelial 
ridges penetrating into the underlying connective tissue were also 
noted.
The underlying connective tissue stroma manifested an 
increased amount of collagen fiber bundles and few number of 
fibroblasts and fibrocytes, in addition to limited number of chronic 
inflammatory cell infiltrates, Figure 4.
Immunohistochemical examination of healthy control gingival 
tissues observed weak Bcl-2 and Ki-67-positive cells only in the basal 
and parabasal layers of the covering epithelium, while lamina propria 
showed negative immunostaining of Bcl-2 and Ki-67 monoclonal 
antibodies, Figure  5a and b. While the overgrowing gingival 
tissue of epileptic patients revealed a strong, positive, nuclear 
immunostaining pattern of Bcl-2 and Ki-67 widely distributed 
throughout the overlying epithelial layers, in the control gingival 
tissues it was mainly located in the basal and suprabasal layers of the 
covering epithelium with no difference in density of staining affinity 
as illustrated in Figure 6a and b. This positive reaction was more 
noticeable within epithelial cells than the connective tissue cells. 
In the lamina propria, Bcl-2 and Ki-67 expressions were observed in 
fibroblasts of hyperplastic gingival tissues only.
Statistical Analyses
Histopathological and immunohistochemical results of this work, 
as well as Chi-square test, revealed that gingival overgrowth 
of epileptic patients was correlated proportionally with Bcl-2 
and Ki-67 expression. Thus, immunohistochemical expression 
was significantly high in gingival tissue of epileptic patients. No 
significant correlation was identified between Bcl-2 and Ki-67 
expression and healthy control gingival tissues [Table  1 and 
Figure 7].
dI s c u s s I o n
DIGO, also referred to as drug-induced gingival enlargement, and 
previously referred to as drug-induced gingival hyperplasia, is a 
noted side effect of more than 15 drugs that have been identified 
as possible causative agents of gingival overgrowth. However, 
phenytoin is more commonly involved.[1-15] Not all patients using 
phenytoin are affected by gingival overgrowth, however, the 
prevalence rate of drug-induced enlargement was reported to vary 
Table 1: Comparison between Bcl-2 and Ki-67 expression in 
epithelium and connective tissue of study and control cases
Variables Number of study cases Number of control cases
Epith. CT Epith. CT
Bcl2 +ve 24 24 8 0
Bcl2 −ve 0 0 0 8
Ki-67 +ve 24 24 8 0
Ki-67 -ve 0 0 0 8
P value 0.01 0.01 0.05 0.05
P-value 0.014* 0.747 0.006* 0.003*, *significant at P≤0.05
Figure 4: Histopathological picture of phenytoin-induced gingival 
overgrowth showing hyperplastic epithelium and elongated slender 
rete processes. The connective tissue shows excessive collagen fiber 
bundles with little chronic inflammatory cells (H and E ×100)
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Figure 7: Histogram showing comparison between Bcl-2 and Ki-67 
immunoreactivity in study and control cases
Figure 5: (a and b) Ki-67 and Bcl-2 antigen-positive nuclei observed 
mainly in the basal and suprabasal layer of control gingival 
epithelium (Streptavidin-Biotin, ×100)
ba
Figure 6: (a and b) Ki-67 and Bcl-2 antigen-positive cells throughout 
the gingival tissues of epileptic patients (Streptavidin-Biotin, ×100)
ba
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from 10% to 15% for phenytoin.[33] Furthermore, gender and age 
may not be relevant risk factors for phenytoin-induced overgrowth 
than other drugs.[34] A correlation with dosage, duration, drug 
concentrations (in blood and whole saliva), and severity extent 
of gingival enlargement has also been suggested, but so many 
variables (sampling technique and pharmacokinetic factors) can 
influence this aspect that it remains controversial.[35-39] However, it 
has been recently reported that patients treated with phenytoin 
solution experience earlier onset of gingival changes and more 
extensive overgrowth than patients using capsules.[36-38]
Clinically, phenytoin-induced gingival overgrowth usually 
starts from the papillary regions. As the process develops, the 
papillae increase in size and the margins and gingival attachment 
may also became involved. The anterior segments and the labial 
gingiva are most commonly involved, but the enlargement may 
also be observed in the molar regions, particularly in the late stages 
of disease, in which the gingivae are firm and pale because of the 
conspicuous fibrous component.[39-44] Some case reports have also 
described overgrowth of edentulous ridges and elsewhere.[45]
The pathogenesis of DIGOs is still not completely understood. 
It has been demonstrated that gingival enlargement has a 
multifactorial nature and is affected by factors such as age, 
demographic variables, genetic predisposition, oral hygiene status, 
pharmacokinetic variables, and molecular and cellular changes in 
gingival tissues.[46-52] Phenytoin can influence the metabolism of 
some age-dependent hormones (i.e., testosterone) which could 
have a direct effect on gingival cells populations.[53] Changes 
in gingival contour seen in DIGO may also be exacerbated by 
plaque-induced gingival inflammation, through a mechanism of 
mechanical and chemical chronic irritation.[54,55]
In the present study, the obtained histopathological results 
of phenytoin-induced gingival overgrowth revealed a marked 
acanthosis, parakeratosis of the covering epithelium with thin 
elongated processes extended toward the connective tissue 
stroma. The underlying connective tissue showed an increased 
amount of collagen fiber bundles, few number of fibroblasts and 
fibrocytes, and some blood vessels, in addition to limited number 
of chronic inflammatory cell infiltrates, Figure 3a and b.
These results were in agreement with the microscopic 
results of many previous studies concerning the effect of 
prolonged intake of phenytoin on the gingival tissue of epileptic 
patients.[56-62] The current results could be attributed to the 
increased production of collagen and protein leading to excessive 
formation of extracellular matrix and collagen fibers with 
reduction of collagenase activity.[63] Moreover, increased levels of 
interleukin-6 and transforming growth factor-b and the decreased 
levels of gamma-interferon observed during prolonged intake of 
phenytoin therapy may help the fibroblast synthesis of collagen 
fibers.[64,65] Similarly, other studies showed complex interactions 
between the drug or phenytoin, gingival tissues, and local released 
mediators.[56-62] Finally, the exact mechanism underlying the 
development of gingival overgrowth due to phenytoin ingestion 
is still unclear until now.[56-65]
On the light of the aforementioned clinical and 
histopathological findings of the current study, proliferation 
of gingival tissue of epileptic patients receiving phenytoin 
and subsequent an increased cell division was confirmed. 
However, several factors, including age, genetic predisposition, 
pharmacokinetic variables, and plaque-induced inflammatory 
changes, are believed to be important in the onset and severity 
of gingival overgrowth. Thus, the possible role of phenytoin 
for enhancement the proliferative activity of gingival tissue in 
epileptic patients was investigated immunohistochemically using 
Bcl-2 and Ki-67 monoclonal antibodies.
Bcl-2 (B-cell lymphoma 2), encoded in humans by the Bcl2 
gene, is the founding member of the Bcl-2 family of regulator 
proteins that control programmed cell death (apoptosis), by 
either inducing (pro-apoptotic) or inhibiting (anti-apoptotic) 
apoptosis.[66-70] Bcl-2 is localized to the outer membrane of 
mitochondria, where it plays an important role in promoting 
cellular survival and inhibiting the actions of pro-apoptotic 
proteins. It is still not clear what biochemical activity of Bcl-2 is 
responsible for its function, but increasing evidence indicates that 
a functional activity of Bcl-2 on the endoplasmic reticulum (ER) 
protects mitochondria under diverse circumstances.[69] Indeed, 
an emerging hypothesis is that, during apoptosis, the Bcl-2 family 
regulates ER-to-mitochondrion communication by BH3-only 
proteins and calcium ions and thereby triggers mitochondrial 
dysfunction and cell death.[68,70,71] Finally, overexpressed Bcl-2 
contributes to transformation of cells by preventing them from 
undergoing apoptosis, as seen in B-cell lymphomas, in which Bcl-2 
is upregulated following a chromosomal translocation.[72]
An increasing evidence indicated that an unusual cell 
proliferation may have a role in the pathogenesis of gingival 
overgrowth with different etiologies, including administration of 
certain drugs, such as phenytoin. The best-known antibody that 
recognizes the proliferating cells or activity of gingival tissue of 
epileptic patients administered phenytoin is Ki-67 monoclonal 
antibody. Ki-67 is a proliferation associated antigen that serves 
as a marker for estimation of tissue growth as it is present in the 
nuclei of proliferating cells located in G1, S, G2, and M phases of 
the cell cycle and absent in quiescent cells lagging in G0 phase, 
suggesting a role for Ki-67 in the early steps of rRNA synthesis.[73-77]
Concerning the immunohistochemical results, all the 
examined samples of normal gingival tissues of this study showed 
Bcl-2 as scattered positive cells in between the basal cells of 
normal gingival epithelium. This reflects the progenitor cell 
role of basal cells, which require the protection of Bcl-2 against 
apoptotic cell death to ensure survival of the entire epithelium. Its 
absence in the suprabasal layers indicates that Bcl2 is not required 
during completion of the differentiation process.[78] Moreover, 
weak positive staining with Ki-67 was detected in the basal and 
suprabasal layers of normal gingival epithelium while lamina 
propria showed negative immunostaining of the same antibody. 
This finding explained the physiological proliferative activity that 
always exists in the basal and suprabasal layers of the normal 
gingival epithelium.[79]
On the other hand, the immunohistochemical findings of 
gingival tissue of epileptic patients revealed a strong, positive, 
nuclear immunoreactivity of Bcl-2 and Ki-67 throughout the 
epithelial cells of the covering epithelium, but mostly in the basal 
and suprabasal layers. While, the connective tissue showed positive 
expression in fibroblasts of hyperplastic gingival tissues. This result 
showed a significant proliferative potential of epithelium and 
connective tissue of epileptic gingival tissue as reflected byBcl-2 
and Ki-6 immunoreactivity which was higher than control tissues. 
In agreement with this result, Nurmenniemi et al.[80] also reported a 
significant increase in numbers of Ki-67-labeled cells in phenytoin-
induced gingival hyperplasia cases compared to healthy controls. 
Saito et al.[81] found that mean rates of Ki-67-positive cells in 
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phenytoin gingival overgrowth patients were significantly higher 
as well than healthy tissues. Saygun et al.,[82] who suggested that 
the underlying mechanism of high gingival fibrosis does not 
involve increased cellular proliferation of the epithelium and the 
gingival overgrowth is caused by excessive extracellular matrix 
deposition.
co n c lu s I o n
The previously mentioned findings of this study confirmed that 
increased expression of Bcl-2 and Ki-67 may have a role in the 
pathogenesis of gingival overgrowth induced by prolonged intake 
of phenytoin. Accordingly, further studies with larger sample size 
will provide more conclusive data on the possible role of enhanced 
proliferative activity of cells in the pathogenesis of gingival 
overgrowth. Finally, more studies are needed to determine 
whether epileptic patients on phenytoin are at high risk of the 
development of neoplasms or not.
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